CDIP1 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA561940-Each-of-1 | In Stock | ₹ 48,905.50 |
PIPA561940 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 48,905.50
GST (18%): ₹ 8,802.99
Total Price: ₹ 57,708.49
Antigen
CDIP1
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CDIP1
Gene Alias
2700048O17Rik; 5730403B10Rik; AU018521; AW742692; C16orf5; CDIP; CDIP1; cell death inducing protein; cell death inducing Trp53 target 1; cell death involved p53-target; cell death-inducing p53 target 1; cell death-inducing p53-target protein 1; Cell death-inducing protein; I1; Lipopolysaccharide-induced tumor necrosis factor-alpha-like protein; LITAFL; LITAF-like protein; Transmembrane protein I1
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
29965
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunocytochemistry, Immunohistochemistry
Concentration
0.05 mg/mL
Formulation
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2
Gene Accession No.
Q9H305
Gene Symbols
CDIP1
Immunogen
Recombinant protein corresponding to Human CDIP1
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Immunogen sequence: CLINDFKDVT HTCPSCKAYI YTYKLLC Highest antigen sequence identity to the following orthologs: Mouse - 93%, Rat - 93%
- The p53 tumor-suppressor gene integrates numerous signals that control cell life and death; loss of its functions contributes to the development of most cancers
- CDIP is a novel pro-apoptotic target gene whose inhibition abrogates p53-mediated apoptotic responses
- Overexpression of CDIP induced apoptosis in transfected cells while siRNA suppression of caspase-8 mRNA blocked this CDIP-induced apoptosis, indicating that the CDIP-dependent apoptosis pathway proceeds through extrinsic cell death pathway
- CDIP may thus represent a novel target for drug design to maximize p53 response and sensitize tumor cells to cancer therapy
- Multiple isoforms of CDIP are known to exist.